The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes: 6-Month Interim Analysis From the First-in-Human Proof-of-Concept Study
Abstract
OBJECTIVE: To assess procedural safety and glycemic indices at 6 months in a first-in-human study of duodenal mucosal resurfacing (DMR), a novel, minimally invasive, upper endoscopic procedure involving hydrothermal ablation of the duodenal mucosa, in patients with type 2 diabetes and HbA1c ≥7.5% (58 mmol/mol) on one or more oral antidiabetic agents. RESEARCH DESIGN AND METHODS: Using novel balloon catheters, DMR was conducted on varying lengths of duodenum in anesthetized patients at a single medical center. RESULTS: A total of 39 patients with type 2 diabetes (screening HbA1c 9.5% [80 mmol/mol]; BMI 31 kg/m2) were treated and included in the interim efficacy analysis: 28 had a long duodenal segment ablated (LS; ∼9.3 cm treated) and 11 had a short segment ablated (SS; ∼3.4 cm treated). Overall, DMR was well tolerated with minimal gastrointestinal symptoms postprocedure. Three patients experienced duodenal stenosis treated successfully by balloon dilation. HbA1c was reduced by 1.2% at 6 months in the full cohort (P < 0.001). More potent glycemic effects were observed among the LS cohort, who experienced a 2.5% reduction in mean HbA1c at 3 months postprocedure vs. 1.2% in the SS group (P < 0.05) and a 1.4% reduction at 6 months vs. 0.7% in the SS group (P = 0.3). This occurred despite net medication reductions in the LS cohort between 0 and 6 months. Among LS patients with a screening HbA1c of 7.5–10% (58–86 mmol/mol) and on stable antidiabetic medications postprocedure, HbA1c was reduced by 1.8% at 6 months (P < 0.01). CONCLUSIONS: Single-procedure DMR elicits a clinically significant improvement in hyperglycemia in patients with type 2 diabetes in the short-term, with acceptable safety and tolerability. Long-term safety, efficacy, and durability and possible mechanisms of action require further investigation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The intragastric balloon and transpyloric shuttle trials included some persons with T2D, but numbers were inadequate to assess safety and efficacy in those with T2D.787–789”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [787]
In the citing paper
“Some endoscopic and orally delivered devices have been approved by the FDA for treatment of obesity, including hydrogel capsules,786 intragastric balloon systems,787–788 a transpyloric shuttle that blocks gastric emptying,789 and gastric aspiration therapy that evacuates partial gastric contents following meals via a variation of a percutaneous endoscopic gastrostomy tube.790”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [787]
In the citing paper
“While weight loss following DMR is modest (~2.5 kg at six months), significant metabolic benefits have been reported.”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [92]
In the citing paper
“Improvements in glycemic control, including a 1.2% reduction in HbA1c at six months, have been observed, particularly following long-segment ablation [92].”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [92]
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 1×
“Despite a wide choice of pharmacological interventions, many patients do not achieve adequate control of hyperglycemia (1).”
BackgroundRubino, F., Nathan, D. M., Eckel, R. H., Schauer, P. R., Alberti, K. G. M. M., Zimmet, P. Z., Del Prato, S., Ji, L., Sadikot, S. M., Herman, W. H., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0236 · Cited by 1,008
Self-citationRubino, F., Forgione, A., Cummings, D. E., Vix, M., Gnuli, D., Mingrone, G., Castagneto, M., & Marescaux, J. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000224726.61448.1b · Cited by 928
Self-citationRubino, F., & Marescaux, J. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000102989.54824.fc · Cited by 617
Self-citationHuman duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP
Theodorakis, M. J., Carlson, O., Michopoulos, S., Doyle, M. E., Juhaszova, M., Petraki, K., & Egan, J. M. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00326.2004 · Cited by 396 · cited 1×
“Duodenal biopsy from humans with diabetes also shows hypertrophy, thickening, and an overgrowth of entero-endocrine cell types (22).”
BackgroundLaferrère, B., Reilly, D., Arias, S., Swerdlow, N., Gorroochurn, P., Bawa, B., Bose, M., Teixeira, J., Stevens, R. D., Wenner, B. R., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002043 · Cited by 384
Jacobsen, S. H., Olesen, S. C., Dirksen, C., Jørgensen, N. B., Bojsen-Møller, K. N., Kielgast, U., Worm, D., Almdal, T., Naver, L. S., Hvolris, L. E., et al. (2012) · Obesity Surgery · doi:10.1007/s11695-012-0621-4 · Cited by 342
Jørgensen, N. B., Jacobsen, S. H., Dirksen, C., Bojsen-Møller, K. N., Naver, L., Hvolris, L., Clausen, T. R., Wulff, B. S., Worm, D., Lindqvist Hansen, D., et al. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00073.2012 · Cited by 313
Bojsen-Møller, K. N., Dirksen, C., Jørgensen, N. B., Jacobsen, S. H., Serup, A. K., Albers, P. H., Hansen, D. L., Worm, D., Naver, L., Kristiansen, V. B., et al. (2014) · Diabetes · doi:10.2337/db13-1307 · Cited by 254
Breen, D. M., Rasmussen, B. A., Kokorovic, A., Wang, R., Cheung, G. W. C., & Lam, T. K. T. (2012) · Nature Medicine · doi:10.1038/nm.2745 · Cited by 209 · cited 1×
“This suggests a potential effect on hepatic glucose production, possibly through an insulin-sensitizing mechanism, in line with previous observations in duodenal-jejunal bypass (17) and Roux-en-Y gastric bypass surgery (18–20).”
Result
Cited by
The science of obesity management: an endocrine society scientific statement
Bray, G. A., Heisel, W. E., Afshin, A., Jensen, M. D., Dietz, W. H., Long, M., Kushner, R. F., Daniels, S. R., Wadden, T. A., Tsai, A. G., et al. (2018) · Endocrine Reviews · doi:10.1210/er.2017-00253 · Cited by 812
Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments
Ruze, R., Liu, T., Zou, X., Song, J., Chen, Y., Xu, R., Yin, X., & Xu, Q. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1161521 · Cited by 799
Mechanick, J. I., Apovian, C., Brethauer, S., Garvey, W. T., Joffe, A. M., Kim, J., Kushner, R. F., Lindquist, R., Pessah-Pollack, R., Seger, J., et al. (2020) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2019.10.025 · Cited by 608
Mechanick, J. I., Apovian, C., Brethauer, S., Garvey, W. T., Joffe, A. M., Kim, J., Kushner, R. F., Lindquist, R., Pessah-Pollack, R., Seger, J., et al. (2019) · Endocrine Practice · doi:10.4158/gl-2019-0406 · Cited by 510
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Metadata
- Authors
- Rajagopalan, H., Cherrington, A. D., Thompson, C. C., Kaplan, L. M., Rubino, F., Mingrone, G., Becerra, P., Rodriguez, P., Vignolo, P., Caplan, J., Rodriguez, L., & Galvao Neto, M. P.
- Affiliations
- Fractyl (United States) (US)
- Vanderbilt University Medical Center (US)
- Brigham and Women's Hospital (US)
- Massachusetts General Hospital (US)
- King's College London (GB)
- Catholic University of Rome, Rome, Italy
- CCO Clinical Center for Diabetes, Obesity and Reflux, Santiago, Chile
- Gastro Obeso Center, São Paulo, Brazil
- Corresponding author
- Rajagopalan, Harith
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-08-12
- Volume
- 39
- Issue
- 12
- Pages
- 2254-2261
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2514895276
- Cited by
- 216
- References
- 35
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 17 · 2023: 14 · 2022: 17 · 2021: 25 · 2020: 34 · 2019: 24 · 2018: 20 · 2017: 32 · 2016: 2
- FWCI
- 26.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Fractyl Laboratories, Inc
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- duodenal mucosal resurfacing, type 2 diabetes, HbA1c reduction, glycemic control, balloon catheter, duodenal stenosis, antidiabetic medication reduction, procedural safety, first-in-human study
- MeSH terms
- Adult, Aged, Blood Glucose, Combined Modality Therapy, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Duodenum, Female, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemic Agents, Intestinal Mucosa, Male, Middle Aged, Pilot Projects, Endoscopy, Gastrointestinal, Bariatric Surgery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes: 6-Month Interim Analysis From the First-in-Human Proof-of-Concept Study. https://app.cochat.ai/papers/10.2337/dc16-0383
- The paper
- Rajagopalan, H., Cherrington, A. D., Thompson, C. C., Kaplan, L. M., Rubino, F., Mingrone, G., Becerra, P., Rodriguez, P., Vignolo, P., Caplan, J., Rodriguez, L., & Galvao Neto, M. P. (2016). Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes: 6-Month Interim Analysis From the First-in-Human Proof-of-Concept Study. Diabetes Care. https://doi.org/10.2337/dc16-0383
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.